Proteomics as a guiding tool for more effective personalized therapy

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Lee, J M ^a   Kohn, E C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ovarian cancer; Proteomics; Therapy

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

BREAST CANCER; CANCER CLASSIFICATION; CANCER SCREENING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEOMICS; SIGNAL TRANSDUCTION; TREATMENT PLANNING; UPREGULATION;

DECISION MAKING; EFFICIENCY; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649427770     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq375     Document Type: Conference Paper

References (26)

1. Ozols RF RS, Thomas G. Principles and Practice of Gynecologic Oncology. 4th edn. Philadelphia: Lippincott, Williams and Wilkins 2005.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
4. Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics 2005; 5: 141-148.
5. Denkert C, Budczies J, Kind T et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006; 66: 10795-10804.
6. Lemaire R, Menguellet SA, Stauber J et al. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 2007; 6: 4127-4134.
7. Simpkins F, Czechowicz JA, Kohn EC et al. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 2005; 6: 647-653.
8. Sheehan KM, Calvert VS, Kay EW et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4: 346-355.
9. Winters M, Dabir B, Kohn EC et al. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 2007; 7: 4066-4068.
10. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 2008; 359: 1757-1765.
11. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-985.
12. Sargent DJ, Conley BA, Allegra C et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Onc 2005; 23: 2020-2027.
13. Dunn L, Demichele A. Genomic predictors of outcome and treatment response in breast cancer. Mol Diagn Ther 2009; 13: 73-90.
14. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer; correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
15. Yanagisawa K, Tomida S, Shimada Y et al. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 858-867.
16. PaoW Kris MG, Ladanyi M et al. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009; 15: 5317-5322.
17. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. The 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, Texas, 2009. Abstr 62.
18. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008: 5:e232.
19. Sledge GW. What is targeted therapy? J Clin Oncol 2005; 23: 1614-1615.
20. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
21. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
22. Posadas EM, Liel MS, Minasian L et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109: 1323-1330.
23. Posadas EM, Kwitkowski V, Kotz HL et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007; 110: 309-317.
24. Lesnock J, Darcy K, Gallion H. Association between reduced BRCA 1 expression and survival inpatients with sporadic epithelial ovarian cancer treated with intraperitoneal versus intravenous cisplatin and paclitaxel: a Gynecologic Oncology Group Study 172. Gynecol Oncol 116: S4.
25. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
26. Shayestech l, Lu Y, Kuo WL et al. PIK3CA is implicated as anoncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.